vida: extract claims from 2026-04-23-glp1-exercise-lifestyle-combination-frontiers-2025

- Source: inbox/queue/2026-04-23-glp1-exercise-lifestyle-combination-frontiers-2025.md
- Domain: health
- Claims: 1, Entities: 0
- Enrichments: 2
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp-1-receptor-agonists-produce-nutritional-deficiencies-in-12-14-percent-of-users-within-6-12-months-requiring-monitoring-infrastructure-current-prescribing-lacks.md

@@ -10,12 +10,17 @@ agent: vida
 scope: causal
 sourcer: IAPAM
 related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]"]
-supports:
-- GLP-1 therapy requires continuous nutritional monitoring infrastructure but 92 percent of patients receive no dietitian support creating a care gap that widens as adoption scales
-reweave_edges:
-- GLP-1 therapy requires continuous nutritional monitoring infrastructure but 92 percent of patients receive no dietitian support creating a care gap that widens as adoption scales|supports|2026-04-12
+supports: ["GLP-1 therapy requires continuous nutritional monitoring infrastructure but 92 percent of patients receive no dietitian support creating a care gap that widens as adoption scales"]
+reweave_edges: ["GLP-1 therapy requires continuous nutritional monitoring infrastructure but 92 percent of patients receive no dietitian support creating a care gap that widens as adoption scales|supports|2026-04-12"]
+related: ["glp-1-receptor-agonists-produce-nutritional-deficiencies-in-12-14-percent-of-users-within-6-12-months-requiring-monitoring-infrastructure-current-prescribing-lacks", "glp-1-therapy-requires-nutritional-monitoring-infrastructure-but-92-percent-receive-no-dietitian-support"]
 ---
 
 # GLP-1 receptor agonists produce nutritional deficiencies in 12-14 percent of users within 6-12 months requiring monitoring infrastructure current prescribing lacks
 
-A large cohort study of 461,382 GLP-1 users found that 12.7% developed new nutritional deficiency diagnoses at 6 months of therapy, rising to 13.6% for vitamin D deficiency by 12 months. Deficiencies in iron, B vitamins, calcium, selenium, and zinc also increased over time. The mechanism is straightforward: GLP-1 receptor agonists suppress appetite broadly, reducing total caloric intake including micronutrient-rich foods. This is not a rare adverse effect but a common one affecting more than one in eight users. The clinical significance is underscored by the first formal multi-society guidance (AHA/ACLM/ASN/OMA/TOS joint advisory in American Journal of Clinical Nutrition, 2025) specifically addressing nutritional monitoring and supplementation for GLP-1 users. IAPAM clinical practice updates from October 2025 through February 2026 document practitioners reporting increasing presentations of GLP-1-related complications including muscle mass loss (sarcopenia), hair loss (telogen effluvium from protein/micronutrient depletion), and bone density concerns. The gap is operational: GLP-1 is being prescribed at unprecedented scale with a simple 'inject and lose weight' narrative, but the medical system lacks the monitoring infrastructure to systematically catch and correct these deficiencies before they produce secondary health effects that may undermine the metabolic benefits of weight loss.
+A large cohort study of 461,382 GLP-1 users found that 12.7% developed new nutritional deficiency diagnoses at 6 months of therapy, rising to 13.6% for vitamin D deficiency by 12 months. Deficiencies in iron, B vitamins, calcium, selenium, and zinc also increased over time. The mechanism is straightforward: GLP-1 receptor agonists suppress appetite broadly, reducing total caloric intake including micronutrient-rich foods. This is not a rare adverse effect but a common one affecting more than one in eight users. The clinical significance is underscored by the first formal multi-society guidance (AHA/ACLM/ASN/OMA/TOS joint advisory in American Journal of Clinical Nutrition, 2025) specifically addressing nutritional monitoring and supplementation for GLP-1 users. IAPAM clinical practice updates from October 2025 through February 2026 document practitioners reporting increasing presentations of GLP-1-related complications including muscle mass loss (sarcopenia), hair loss (telogen effluvium from protein/micronutrient depletion), and bone density concerns. The gap is operational: GLP-1 is being prescribed at unprecedented scale with a simple 'inject and lose weight' narrative, but the medical system lacks the monitoring infrastructure to systematically catch and correct these deficiencies before they produce secondary health effects that may undermine the metabolic benefits of weight loss.
+
+## Extending Evidence
+
+**Source:** Frontiers in Clinical Diabetes and Healthcare 2025 review
+
+GLP-1 RAs reduce appetite and gastric emptying which can limit protein intake and nutrient absorption necessary for muscle preservation. Adequate protein intake of 1.2-2.0 g/kg body weight is recommended depending on training status. This provides the specific mechanism by which GLP-1 creates nutritional deficiency risk.

domains/health/glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation.md

@@ -10,16 +10,10 @@ agent: vida
 scope: causal
 sourcer: Tzang et al. (Lancet eClinicalMedicine)
 related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]", "[[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action]]"]
-related:
-- glp-1-receptor-agonists-produce-nutritional-deficiencies-in-12-14-percent-of-users-within-6-12-months-requiring-monitoring-infrastructure-current-prescribing-lacks
-reweave_edges:
-- glp-1-receptor-agonists-produce-nutritional-deficiencies-in-12-14-percent-of-users-within-6-12-months-requiring-monitoring-infrastructure-current-prescribing-lacks|related|2026-04-09
-- GLP-1 therapy requires continuous nutritional monitoring infrastructure but 92 percent of patients receive no dietitian support creating a care gap that widens as adoption scales|supports|2026-04-12
-- Comprehensive behavioral wraparound may enable durable weight maintenance post-GLP-1 cessation, challenging the unconditional continuous-delivery requirement|challenges|2026-04-14
-supports:
-- GLP-1 therapy requires continuous nutritional monitoring infrastructure but 92 percent of patients receive no dietitian support creating a care gap that widens as adoption scales
-challenges:
-- Comprehensive behavioral wraparound may enable durable weight maintenance post-GLP-1 cessation, challenging the unconditional continuous-delivery requirement
+related: ["glp-1-receptor-agonists-produce-nutritional-deficiencies-in-12-14-percent-of-users-within-6-12-months-requiring-monitoring-infrastructure-current-prescribing-lacks", "glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss-suggesting-glp1r-specific-cardiac-mechanism", "semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss", "comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation", "glp1-receptor-agonists-provide-cardiovascular-benefits-through-weight-independent-mechanisms"]
+reweave_edges: ["glp-1-receptor-agonists-produce-nutritional-deficiencies-in-12-14-percent-of-users-within-6-12-months-requiring-monitoring-infrastructure-current-prescribing-lacks|related|2026-04-09", "GLP-1 therapy requires continuous nutritional monitoring infrastructure but 92 percent of patients receive no dietitian support creating a care gap that widens as adoption scales|supports|2026-04-12", "Comprehensive behavioral wraparound may enable durable weight maintenance post-GLP-1 cessation, challenging the unconditional continuous-delivery requirement|challenges|2026-04-14"]
+supports: ["GLP-1 therapy requires continuous nutritional monitoring infrastructure but 92 percent of patients receive no dietitian support creating a care gap that widens as adoption scales"]
+challenges: ["Comprehensive behavioral wraparound may enable durable weight maintenance post-GLP-1 cessation, challenging the unconditional continuous-delivery requirement"]
 ---
 
 # GLP-1 receptor agonists require continuous treatment because metabolic benefits reverse within 28-52 weeks of discontinuation
@@ -31,3 +25,10 @@ Meta-analysis of 18 randomized controlled trials (n=3,771) demonstrates that GLP
 **Source:** WHO December 2025 guideline conditional framing
 
 WHO's conditional recommendation acknowledges 'limited long-term evidence' and 'durability of effects unclear' as reasons for not issuing a strong recommendation. The guideline's caution about discontinuation effects aligns with the 28-52 week reversal timeline documented in clinical trials.
+
+
+## Extending Evidence
+
+**Source:** Frontiers in Clinical Diabetes and Healthcare 2025 review
+
+Exercise helps preserve muscle mass and sustain weight loss after GLP-1 cessation. The review states that stopping GLP-1 therapy alone leads to weight regain, but exercise provides a partial mitigation pathway. Future obesity management will likely prioritize integrated approaches (pharmacotherapy + lifestyle) rather than pharmacotherapy replacing lifestyle.

domains/health/glp1-appetite-suppression-creates-protein-deficiency-pathway-requiring-resistance-training-mitigation.md

@@ -0,0 +1,18 @@
+---
+type: claim
+domain: health
+description: GLP-1 agonists reduce appetite and gastric emptying which limits protein intake and nutrient absorption, creating muscle loss risk that resistance training specifically mitigates through preservation of lean mass during weight loss
+confidence: experimental
+source: Frontiers in Clinical Diabetes and Healthcare 2025 review, RCT evidence on resistance training + GLP-1 combinations
+created: 2026-04-23
+title: GLP-1 appetite suppression creates a protein deficiency pathway that causes muscle loss, making resistance training mechanistically necessary rather than complementary
+agent: vida
+sourced_from: health/2026-04-23-glp1-exercise-lifestyle-combination-frontiers-2025.md
+scope: causal
+sourcer: Frontiers in Clinical Diabetes and Healthcare
+related: ["glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "glp-1-receptor-agonists-produce-nutritional-deficiencies-in-12-14-percent-of-users-within-6-12-months-requiring-monitoring-infrastructure-current-prescribing-lacks", "glp1-hfpef-creates-competing-mechanisms-cardiac-benefit-versus-sarcopenic-malnutrition-risk"]
+---
+
+# GLP-1 appetite suppression creates a protein deficiency pathway that causes muscle loss, making resistance training mechanistically necessary rather than complementary
+
+GLP-1 receptor agonists produce greater short-term weight loss than exercise alone, but this pharmacological advantage creates a specific risk: appetite suppression and reduced gastric emptying limit protein intake and nutrient absorption necessary for muscle preservation. The review identifies resistance training as 'the single most effective tool for preserving lean muscle during weight loss' and recommends protein intake of 1.2-2.0 g/kg body weight depending on training status. Recent RCTs demonstrate that combining GLP-1 + exercise yields additive benefits beyond either intervention alone, with greater reductions in metabolic syndrome severity, abdominal obesity, oxidative stress, and inflammation. Critically, exercise helps preserve muscle mass and sustain weight loss after GLP-1 cessation, when stopping GLP-1 therapy alone leads to weight regain. This is not simply 'exercise is good' — it's a specific mechanistic requirement where the drug's primary mechanism (appetite suppression) creates a downstream risk (protein deficiency → muscle loss) that requires behavioral intervention (resistance training + adequate protein) to prevent harm. The combination is additive because each addresses different failure modes: GLP-1 excels at short-term weight loss while exercise is superior for lean mass preservation and post-cessation maintenance.

inbox/archive/health/2026-04-23-glp1-exercise-lifestyle-combination-frontiers-2025.md

@@ -7,9 +7,12 @@ date: 2025-01-01
 domain: health
 secondary_domains: []
 format: peer-reviewed review
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-04-23
 priority: medium
 tags: [glp-1, exercise, lifestyle, muscle-preservation, resistance-training, long-term-outcomes, behavioral-complement]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content